Epidemiology of Hepatitis B Virus Infection in China: Current Status and Challenges

Yong-Ping Yan, Hai-Xia Su, Zhao-Hua Ji, Zhong-Jun Shao and Zhong-Shu Pu

Department of Epidemiology, and the Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Fourth Military Medical University, Xi’an, Shaanxi, China

Abstract

The prevalence of hepatitis B is high in China. Based on the National Disease Supervision Information Management System of China, the mean reported incidence of hepatitis B was 84.3 per 100,000 in China between 2005 and 2010. There are differences in population distribution based on region and ethnic group. Here, risk factors, virological characteristics, and prophylaxis of hepatitis B in China are reviewed. Although the prevalence of HBV infection is gradually declining, there are many challenges in HBV infection control, including higher prevalence in floating population, poor compliance of antiviral therapy, and high disease burden.

© 2014 The Second Affiliated Hospital of Chongqing Medical University. Published by XIA & HE Publishing Ltd. All rights reserved.

Introduction

Worldwide, China has been identified as an area with a high prevalence of hepatitis B virus (HBV) infection. According to a national cross-sectional seroepidemiological survey in 1992, 120 million people in China were afflicted with HBV infection, with an infection rate of approximately 60% and prevalence of HBV surface antigen (HBsAg) carriers estimated at 9.8%. The nationwide survey in 2006 showed that the prevalence of HBsAg carrier was reduced to less than 8.0% and the HBsAg prevalence among children aged <5 years was only 1.0%. Based on the prevalence of HBsAg and HBV infection obtained from the two national seroepidemiological surveys, the numbers of HBV-infected patients and HBsAg carriers have decreased by an estimated 80 million and 20 million, respectively, since 1992 to 2006.

The characteristics of notified incidence of hepatitis B in China

Since 2004, patients with hepatitis B identified at the institutions involved in disease control and prevention, blood collection, and supply in China are directly reported within 24 hours to the different health departments via the National Disease Supervision Information Management System (NDSIMS). The notified incidence of hepatitis B is estimated based on these reported cases.

Time and regional distribution

For many years, the number of hepatitis B cases reported to NDSIMS has ranked first among all legally notifiable infectious diseases, accounting for approximately a third of the total cases. The reported incidence of hepatitis B gradually increased threefold from 21.5 per 100,000 to 89.0 per 100,000 in 2007, followed by a slow decline to 79.5 per 100,000 in 2010. The mean reported incidence of hepatitis B was 84.3 per 100,000 in China during the period 2005 to 2010.

In 31 provinces in China, the reported incidences of hepatitis B varied greatly. The lowest mean reported incidence from 2005 to 2010 was in Tibet Autonomous Region (14.6 per 100,000), followed by Jiangsu Province (21.3 per 100,000). The highest was reported in Qinghai Province (283.0 per 100,000), followed by Gansu Province (225.7 per 100,000 persons). The geographical distribution of mean reported incidence of hepatitis B in 31 provinces of China between 2005 and 2010 is shown in Fig. 1.

Population distribution

Among the reported cases of hepatitis B in China from 2005 to 2007, the incidence rate was lowest in children aged <15

Keywords: Hepatitis B; Epidemiology; Distribution; Prophylaxis; Challenges.

Abbreviations: CDC, Center for Disease Control and Prevention; EPI, Expanded Program on Immunization; GWAS, genome wide association study; HBSAg, HBV surface antigen; HBeAg, HBV e antigen; HBV, hepatitis B virus; HLB, hepatitis B immune globulin; HLA-C, human leukocyte antigen C; NAT, nucleic acid testing; NDSIMS, National Disease Supervision Information Management System; OBI, occult HBV infection; PBMC, mother’s peripheral blood mononuclear cells; PCR, polymerase chain reaction; RCT, randomized controlled trial; STD, sexually transmitted disease; UBE2L3, ubiquitin-conjugating enzyme E2 L3.

Received: 23 December 2013; Revised: 7 February 2014; Accepted: 10 February 2014

DOI of original article: 10.14218/JCTH.2013.00030.

Correspondence to: Yong-Ping Yan, Department of Epidemiology, School of Public Health, The Fourth Military Medical University, No. 169, Changle West Road, Xi’an 710032, China. Tel: +86-29-84774868, Fax: +86-29-84774868, E-mail: yanyping@fmmu.edu.cn

Journal of Clinical and Translational Hepatology 2014 vol. 2 | 15-22

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
years. The incidence rate of acute hepatitis B was high among adults aged \( \geq 15 \) years, with the highest incidence rate observed in the population aged 20–29 years. A higher incidence rate of hepatitis B was found in men than women at each age group.\(^{12}\) The male to female ratio of the reported cases of acute hepatitis B was 2.21:1, with most patients aged between 15 and 45 years.\(^{13}\) Acute hepatitis B was detected in each occupation, with the top 3 being farmers (44.3%), students (12.4%), and workers (11.1%).

**Role and issues of the national notified data**

The reported data has been an important evidence-based reference tool to evaluate the risk of hepatitis B for many years and in shaping health policy, such as free neonatal HBV vaccination in China. In addition, hepatitis B was listed as one of the high-priority diseases in the National Key Projects on Prevention and Control of Infectious Diseases initiated in 2008. However, some issues still persist in China’s network-based infectious disease reporting system. For example, the problem of repeated case reports detected between 2004 and 2008 still remains unresolved, with the repeated report rate up to 29.0% in some areas.\(^{14,15}\) In addition, implementation of reporting standards is inconsistent. For example, many HBsAg carriers were reported as acute cases, and the real reported incidence rate of hepatitis B was only about one-third of the reported incidence according to a study from Chinese Center for Disease Control and Prevention (China CDC).\(^{16}\) Therefore, the need for strong training of grass-roots infectious disease physicians and unified standards for acute hepatitis B case reporting to improve the functioning of China’s network-based infectious disease reporting system cannot be overstated.\(^{12}\)

**Risk factors and transmission routes of HBV infection in China**

HBV is mainly transmitted through the blood, with mother-to-infant, blood-borne, and sexual transmission constituting the major routes.

**Mother-to-infant transmission and risk factors**

Prior to the wide availability of HBV vaccination, it was found that mother-to-infant transmission occurred in 10%–30% infants from HBsAg-positive mothers, while 70%–90% of the infants born to HBsAg and HBeAg double positive mothers developed chronic HBV infections.\(^{17,18}\) Prior to 2002, the mother-to-infant HBV transmission was approximately 16%–45%.\(^{19,20}\) The rate of transmission has since been significantly reduced to approximately 3%–5% with the initiation of comprehensive HBV vaccination. However, it was still prevalent up to 7.3% in some areas. The risk factors include HBsAg/HBeAg double positive mothers, untimely HBV vaccination, high HBV DNA viral load, sexual behavior during pregnancy, and untimely HBV vaccination of low-birth-weight and premature infants.\(^{21,22}\) Furthermore, amniocentesis performed on HBsAg+ mothers may also increase the risk for vertical transmission. A significantly higher vertical transmission rate was observed in the amniocentesis group vs. the control group (50.0% vs. 4.5%), if the maternal HBV DNA levels were \( \geq 7 \) log\( _{10} \) copies/ml.\(^{23}\)

**Blood-borne transmission and risk factors**

Historically, unsafe blood transfusion or use of polluted blood products accounted for most of the HBV transmission in
In the 1960s, the incidence of hepatitis reached 50% after blood transfusion. Serological screening of blood donors for hepatitis virus was done until the late 1970s, with routine testing for HBsAg since the early 1980s. Since then, HBV transmission through unsafe blood transfusion has been effectively controlled. Stringent HBsAg screening of blood donors since the Blood Donation Law of the People’s Republic of China in 1999 led to fewer HBV infections caused by blood transmission or transfusion of blood products. An investigation of risk factors of acute hepatitis B among eight provinces in China conducted by China CDC showed that populations with a history of paid blood donation and blood transfusion constituted approximately 3% and 1% of HBV-infected populations, respectively, suggesting that blood transmission is no longer the major transmission route. However, blood-borne transmission of HBV still remains. A population-based case-control study in Shanghai showed that invasive medical procedures, sharing shavers and towels with HBV carriers, body care and beauty treatments were independent risk factors for acute hepatitis B. In addition, pedicures in bathing centers, tattooing and ear piercing may also transmit HBV.

It is estimated that risk of HBV infection by blood transfusion is one in 18,000 in Shenzhen, China, which is higher than Europe, North America and Australia (ranging from 1/70000 to 1/130000). In specific populations, such as hemodialysis patients (20 hemodialysis units of Beijing), the prevalence of HBsAg was only 7.0%, which showed that infection control measures are effective. Nucleic acid testing (NAT) can be used to identify occult HBV infection and HBV infection during treatment window. However, such testing was not involved in the routine detection based on the Blood Donation Law of the People’s Republic of China and the associated administrative regulations. Currently, NAT is only employed for the screening of blood donors in a few large cities and blood stations.

**Sexual transmission and risk factors**

Sexual contact with HBV-infected individuals is considered another major route of HBV infection. In North America and Western Europe where the HBsAg prevalence is lower than 1%, HBV infection spreads through unprotected sexual behaviors and intravenous drug use. Unprotected sexual contact with HBV-infected individuals, especially with multiple sexual partners, increases the risk of HBV infection. Sexual contact is a major risk factor of HBV infection in America, Taiwan, Canada, and UK, including having multiple sexual partners, male homosexuality, having sex with HBV carriers, and heterosexual contact.

Prior to reforms and opening up of China, HBV transmission through sexual contact was confined to husband and wife. However, changing attitudes toward sex led to resurgence of sexually transmitted diseases (STD) such as syphilis, with rising prevalence of HBV infection through sexual contact transmission. Results from the 2006 national seroepidemiological survey of HBV infection showed that the HBsAg prevalence was 10.5% in populations aged 20–30 years and 5.4% in populations aged 15–19 years, suggesting significance of transmission of HBV through sexual contact in a sexually active population. In addition, a study to investigate the prevalence of hepatitis B in Shandong Province from 1990 to 2007 showed that 35.7% of the reported cases were aged from 15 to 29 years, and the prevalence of HBV infection increased from 7.5% in 2004 to 10.3% in 2006 among homosexuals. These results suggested that efforts to vaccinate adults against HBV should be strengthened in addition to routine immunization and vaccination supplementation among children aged less than 15 years, to effectively control the sexual transmission of HBV in adults.

Additionally, host susceptibility is an important risk factor for outcome of HBV infection. Recently, a three-phase genome wide association study (GWAS) on HBV carriers and controls from the general population highlighted the importance of human leukocyte antigen (HLA)-C and ubiquitin conjugating enzyme E2 L3 (UBE2L3) in the clearance of HBV infection in addition to HLA-DP and HLA-DQ.

**Virological characteristics of HBV infection in China**

**HBV genotype and subgenotype**

Nine HBV genotypes (A–I) have been identified based on 8% or more differences in viral whole-genome sequence. In China, five genotypes A–E were detected. Genotypes C and B were the predominant strains in patients with chronic HBV infection, which accounted for about 60% and 12%, respectively. Genotype B was more frequently detected in acute HBV infection compared with chronic hepatitis B and acute-on-chronic liver failure. HBV genotypes have a distinct geographical distribution. Genotype C was dominant in the northern region of China; genotypes B and C were common in the south; genotype D was often found among ethnic minorities in Tibet, Xinjiang, and Gansu provinces; genotype A was rare; and genotype E was only found among Dai Nationality in Yunnan Province. The genotype data from nine provinces showed that genotype C was predominant in the eastern (Shandong and Jiangsu), southern (Guangdong and Guangxi), northern (Jilin and Beijing), and central regions (Henan and Hebei) (Table 1). In the western region (Tibet, Xinjiang, and Qinghai), genotype D was more common, especially in Tibetans and Uighurs.

For hepatitis B virus in China, five genotypes A–E were detected. The prevalence of HBsAg was only 7.0%, which showed that infection control measures are effective. NAT is only employed for the screening of blood donors in a few large cities and blood stations.

Mixed genotype infections were common in each of the regions. Mixed genotypes B and C were most frequently detected, followed by genotypes C and D. Mixed genotypes B and D, A and C, or B, C, and D were rare. In the southern region, including Tibet and Xinjiang provinces, the proportion of mixed infection of genotype C and D was higher, and recombinations of C and D, B and C
were often detected,47,53,54 The heterogeneity of C/D recombinants was more than 8% compared with genotypes A, B, D, E, or F but was 3.8%–8.0% compared with genotype C based on phylogenetic analysis.53 The site of recombination with genotype D was located in the preS2/S region, spanning nt 10–799 in some isolates and nt 10–1499 in the other isolates.55,56 In other regions of the genome, the sequences of recombinant strains were similar to genotype C.

Occult HBV infection

Occult HBV infection (OBI) is defined as the persistence of viral genomes in the liver tissue or the serum from HBsAg-negative individuals.57 OBI may persist in the host for years without obvious symptoms of overt HBV infection,58 or it may develop into hepatitis, cirrhosis, or HCC.59 China is a highly endemic area for HBV infection, and several studies reported prevalence of OBI in different populations. Based on detection of nested polymerase chain reaction (PCR) and real-time PCR, the prevalence of OBI was 0.8% (9/1146)59 among healthy young adults in Harbin, all of whom received three doses of the HBV vaccine. With the HBsAg(−), anti-HBs(+) and anti-HBc(+) vaccines, the rate of OBI was close to 28.8% in Qidong.61 The occult infection may be due to absent or inadequate response to the inoculated HB vaccine61 or from infected mothers.60 Among mother-teenager pairs, OBI prevalence in mothers was 10.0% (6/60), which was significantly higher than 2.0% (2/101) in teenagers.62 The family members of patients with chronic HBV infection were considered high-risk population, with OBI prevalence up to 11%.63 In our previous study, the prevalence of OBI was 4.9% (9/183) in HB-vaccinated infants from HBsAg-positive mothers.64 and their anti-HBs levels were lower. In patients with HBsAg-negative chronic disease and HCC patients, the prevalence of occult HBV infection reached 28.3% (45/159) and 70.4% (95/135), respectively.64

According to reports mentioned above, the strains associated with occult infection were genotype C, B, and C/D recombinant. Some strains harbor G145R mutations in “a” determent, where mostly had few escape mutations. The viral loads were almost not more than 10⁵ copies/ml. However, occult HBV may be transmitted not only by blood transfusion or organ transplantation, but also between relatives or from HBV infected mothers.65 Therefore, more attention should be paid to occult infection in order to better control the spread of HBV infection.

Immunization prevention of hepatitis B in China

Vaccination against HBV

The Ministry of Health of China has implemented a series of regulations involving HBV vaccination since 1992. However, unlike other Expanded Program on Immunization (EPI) vaccines, families had to pay for the HBV vaccine before 2001. To encourage cost-effective immunization, the Chinese government decided to integrate HBV vaccination into the EPI, requiring local authorities at all levels to provide free HBV vaccine to all infants from 2002, with the families only paying the service fee. In 2005, The Chinese government finally adopted a completely free HBV vaccination program for all neonates.66 Following a series of interventions, prevalence of HBV infection has significantly declined from 9.8% in 1992 to 7.2% in 2006 in China.67 In 2009, all youths in China aged below 15 years were vaccinated. The rate of HBV immunization coverage has increased each year since 1992. A study conducted in Zhejiang Province showed that by 1997, the HBV immunization coverage rate for newborns receiving their first dose reached 96.1% and for those receiving three doses reached 93.0%.68 Data obtained from a Chinese survey revealed that after completion of the three-dose HBV vaccination regimen, approximately 90%–95% of healthy individuals exhibited protective levels of the anti-HBs antibody.69 Vaccination compliance was the lowest among adolescents (35.9%) and medicaid recipients (29.7%) who received the varicella vaccine and among younger adults who received the hepatitis A vaccine (25%–35%).70 Similarly, 35–45% of subjects failed to complete the HBV vaccination series.

Passive immunizations with HBIG

Hepatitis B immune globulin (HBIG) is a human polyclonal HBV immunoglobulin preparation containing isolated human plasma protein (50 mg/ml) consisting of at least 95% human polyclonal IgG antibodies. After administration, HBIG is immediately and completely bioavailable in the recipient’s circulation and adequately distributed between plasma and the extravascular fluid. Use of HB vaccine and HBIG in babies born to HBsAg positive mothers after 12 hours of birth tremendously reduces the HBV infection rate. HBIG was also widely used in the prevention of HBV uterine transmission. In 1995, antepartum treatment that could significantly and safely reduce the failure of postnatal passive or active HBV immunization was reported in China. The treatment involved administration of HBIG 200 IU intramuscularly once a month at the third, second, and first
Intrauterine transmission of HBV cannot be completely interrupted

Intrauterine transmission of HBV is defined as HBV infection caused by the transmission of HBV from pregnant women to fetus through placenta, which is one route of mother-to-infant transmission. Currently, many hypotheses have been proposed to explain the mechanism of intrauterine transmission of HBV. The first hypothesis relates to HBV transmission from the mother’s peripheral blood mononuclear cells (PBMC) to the fetus via placental barrier. Secondly, HBV infection rate among different layers of placental cells gradually decreases from the maternal side to the fetal side, which supports the hypothesis that intrauterine HBV transmission may be caused through “cellular transfer” in the placenta. Thirdly, transplacental leakage during threatened preterm labor and abortion leads to fetal HBV infection through the leakage of maternal blood into the blood circulation, thereby inducing intrauterine transmission of HBV. Currently, it is believed that administration of antiviral drugs at the late stage of pregnancy can effectively prevent the occurrence of mother-to-infant transmission of HBV.

Low standardization and poor compliance of antiviral therapy for patients

Patients with chronic hepatitis B suffer from problems associated with long-time antiviral therapy, high medical cost, possible viral mutations, and relapse, which easily lead to low compliance. Our previous study (unpublished data) showed that among outpatients with hepatitis B, approximately 33% of the patients with chronic hepatitis B were not aware of currently effective drugs and antiviral therapies for HBV, and 52.8% never underwent standard antiviral therapy for HBV. Among the patients undergoing treatment, approximately 32.5% received interferon treatment, and the remainder of patients was mostly treated with nucleoside/nucleotide drugs. While 87.2% received medications prescribed, 62.3% stopped taking medications without reaching the full course of therapy due to economic difficulties. Therefore, educational intervention for hepatitis B prevention and control should be conducted in China, notably in rural areas. In the future, it will be important to educate patients on how antiviral therapies can prevent and slow poor outcomes in order to increase therapeutic compliance.

High hepatitis B-caused disease burden

In addition to health consequences, hepatitis B leads to high economic burden for patients, family, and society. It is known that approximately 15%–40% of HBV-infected individuals finally will develop hepatic cirrhosis, hepatic failure, or hepatocellular carcinoma. It was reported that the annual direct cost of inpatients due to hepatitis B was 41,242.9 RMB Yuan in Guangzhou, including the direct medical cost of 39,097.9 RMB Yuan and direct non-medical cost of 2,145.0 RMB Yuan. The direct cost gradually increased with the
aggravation of the disease, of which liver transplantation was associated with the highest cost (119,268.6 RMB Yuan), followed by severe hepatitis B (73,631.0 RMB Yuan) and acute hepatitis B (12,443.9 RMB Yuan). Another study in Ningxia (2010) demonstrated that the annual direct medical and non-medical patient costs due to hepatitis B-related diseases were 26,199.23 and 2,086.53 RMB Yuan, respectively, and the annual direct, indirect and intangible economic burdens were 28,285.76, 3,315.63, and 56,366.41 RMB Yuan, respectively, with a gross economic burden of 87,967.80 RMB Yuan. In addition, it was found that the direct economic burden of the patients with hepatitis B-related diseases almost approximated the patients’ annual family income, which was three-fold greater than the mean family income. In 2010, a total of 20,000 cases of chronic hepatitis B were reported in Shandong Province, and the annual direct, indirect, intangible, and gross economic burdens were 0.618, 0.105, 1.825, and 2.548 billion RMB Yuan, respectively, with chronic hepatitis B-related gross cost accounting for approximately 0.06% of mean per capita gross domestic product (GDP) for the whole province. Therefore, a search for appropriate interventions to reduce the economic burden is of great practical significance in allocating the limited resources and formulating the health decisions and control strategy for hepatitis B.

Conclusions

With the strengthening of hepatitis B control implementation by the Chinese government, the prevalence of HBV infection is gradually declining in China. Notably, hepatitis B has been classified as one of three communicable diseases that are on high priority with the Chinese government since 2008. In total, 15 national demonstration areas for infectious disease prevention and control program have been initiated, with an investment of over one billion RMB Yuan. In addition to investigating the high risk factors of hepatitis B, vaccination has been extended to adults, and standardized antiviral therapy and educational programs have been implemented in rural areas. These measures greatly facilitated the control of hepatitis B in China. A new national seroepidemiological survey is required in the next three to five years to obtain the real prevalence and control of hepatitis B in China to date, in order to develop a revised strategy.

Conflict of interest

None

Author contributions

Designing the review (YPY), writing the paper (YPY, HXS, ZJH, ZJS, and ZSP).

Supportive foundations: This work was supported by China Special Grant for the Prevention and Control of Infection Diseases (2012ZX10004907) and National Nature Science Foundation of China (No. 81072354 and 81370082).

References

[1] Xia GL, Liu CB, Cao HL, Bi SL, Zhan MY, Su CA, et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, and D virus infections in China. Int Hepatol Commun 1996;5:62–72.
[2] Liang XF, Bi SL, Yang WZ, Wang LD, Cui G, Cui FQ, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009;27:6550–6557.
[3] Liu YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582–592.
[4] El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264–1273.
[5] Wang LP, Guo Q, Zhang CX, Guo Y, Zhao ZX, Ma JQ, et al. National investigation into and analysis of hepatitis B reporting quality in 2006. Chinese Journal of Disease Control and Prevention 2009;13 69–71.
[6] Health CsMo. China Health Statistics Yearbook of 2005. Peking Union Medical College Press 2005.
[7] Health CsMo. China Health Statistics Yearbook of 2006. Peking Union Medical College Press 2006:230–238.
[8] Health CsMo. China Health Statistics Yearbook of 2007. Peking Union Medical College Press 2007:226–233.
[9] Health CsMo. China Health Statistics Yearbook of 2008. Peking Union Medical College Press 2008:198–205.
[10] Health CsMo. China Health Statistics Yearbook of 2009. Peking Union Medical College Press 2009:237–244.
[11] Health CsMo. China Health Statistics Yearbook of 2010. Peking Union Medical College Press 2010.
[12] Cui FQ, Wang FZ, Zheng W, Chen YS, Gong XH, Wang HQ, Liang XF. Analysis on Reported Cases of Hepatitis B in China in 2005–2007. Chinese Journal of Vaccines and Immunization 2008;14:413–417.
[13] Hou MC, Wu JC, Kuo BI, Sheng WY, Chen TZ, Lee SD, Lo KJ. Heterosexual transmission as the most common route of acute hepatitis B virus infection among adults in Taiwan—the importance of extending vaccination to susceptible adults. J Infect Dis 1993;167:938–941.
[14] Chen Y, Liu LF, Hu J, X., Wang Y, Fan G. The problems existed in the work of hepatitis B virus case report and its recommendations. Occupation and Health 2006;22:2247–2247.
[15] Chen Y, Liu LF, Hu JL, Wang Y, Fan G. Analysis and investigation on case reporting quality of hepatitis B. J Langsu Prev Med 2006;17:9–11.
[16] Wang FZ, Cui FQ, Lu Y, Chen YS, Zheng W, Liang XF. Analysis on reported hepatitis B cases on pilot surveillance in 18 counties of 9 provinces of China. Chinese Journal of Vaccines and Immunization 2007;13:309–312.
[17] Wiseman E, Fraser MA, Holden S, Glass A, Kdson BL, Heron LG, Maley MW, Ayres A, Locranini SA, Levy MT. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009;190:489–492.
[18] Xu WM, Cui YT, Wang L, Yang H, Liang QZ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S, Atkins M. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomised, double-blind, placebo-controlled study. J Viral Hepat 2009;16:94–103.
[19] Wang JS, Zhu QR. Interruption of the transmission of hepatitis B virus from mother to babies. Chinese journal of hepatology 2002;10:308–310.
[20] Zhu QR, Duan SC. Transmission from mother to baby of the hepatitis B virus. Chinese Journal of Infectious Diseases 1989;7:159–161.
[21] Shao ZJ, Xu DZ, Xu JQ, Li JH, Yan YP, Men K, Wang XG, Zhang YZ, Yang QF, Zhang LH. Maternal hepatitis B virus (HBV) DNA positivity and sexual intercourse are associated with HBV intrauterine transmission in China: a prospective case-control study. J Gastroenterol Hepatol 2007;22:165–170.
[22] Cui HC, Yan YP, Shao ZJ, Xu DZ, Men K, Xu JQ, Li J. Follow-up study on relationship between hepatitis B e antigens and d intrabery HBV infection after imm unoprophylaxis. Chinese Journal of Public Health 2006;22:824–826.
[23] Yi W, Pan CQ, Hao J, Hu Y, Liu M, Li L, Liang D. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J Hepatol 2014;60:523–529.
[24] Wang ST, Weng XZ. Five cases of the same serum hepatitis caused by blood transfusion. Journal of Peking University (Health Sciences) 1960;1:014.
[25] Lu FM, Liu T, Liu S, Zhuang H. Epidemiology and prevention of hepatitis B virus infection in China. J Viral Hepatol 2010;17 (Suppl 1):1–9.
[26] Zhang HW, Yin JH, Li YL, Li CZ, Ren H, Gu CY, Wu HY, Liang XS, Zhang P, Zhao JF, Tan XJ, Wu SL, Schaefer S, Cao GW. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut 2008;57:1713–1720.
[27] Jia JQ, Li LJ. The guideline of prevention and treatment for chronic hepatitis B (2000 version). Chinese Journal of Clinical Hepatology 2011;27:113–128.
[28] Shang G, Seed CR, Wang F, Nie D, Farrugia A. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. Transfusion 2007;47:529–539.
[29] Veliati C, Forniati L, Beruffi L, Romano L, Zanetti A. Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001–2003). Euro Surveill 2005;10:12–14.
[30] Alvarez do Barrio M, Gonzalez Diez R, Hernandez Sanchez JM, Oyonarte Gomez S. Residual risk of transfusion-transmitted viral infections in Spain,
Yan YP et al: Epidemiology of HBV infection in China

1997–2002, and impact of nucleic acid testing. Euro Surveill 2005;10:20–
22. Prevalence of HBV genotypes A, C, D of hepatitis B virus identified in China. J Gen Virol 2005;86:985–990.

[31] Chiavetta JA, Esborad M, Newman A, He Y, Driezen P, Deeks S, Hone DE, O'Brien SF, Sher G. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990–2000. CMAJ 2003;169:767–777.

[32] Yu Y, Yan R, Duan Z, Norris JL, Wang L, Jiang Y, Xing W, Chen Y, Xiao Y, Li L. Prevalence and risk factors of hepatitis C and B virus infections in hemodialysis patients and their spouses: A multicenter study in Beijing, China. J Viral Hepat 2003;10:425–432.

[33] Alter MJ, Margolis HS. The emergence of hepatitis B as a sexually transmitted disease. Med Clin North Am 1990;74:1529–1541.

[34] Daniels D, Cray G, Sasley A. Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ 2009;58:1–27.

[35] Zou S, Zhang J, Tepper M, Giulivi A, Baptiste B, Predy G, Poliquin D, Morin M, Jones D, Lowewen J, Gonenowi K, Moses S, Elliott L. Enhanced surveillance of acute hepatitis B and C in four health regions in Canada, 1998 to 1999. Can J Infect Dis 2001;12:357–363.

[36] Hahn J, Ramsay M, Balogun K, Edmunds WJ, Mortimer P. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995–2000: implications for prevention policy. J Clin Virol 2004;29:211–220.

[37] Wu Q, Li Z, Fan J. A seroepidemiological study on sexually transmitted HBV infection. Zhonggua Liu Xing Bing Xue Za Zhi 1994;15:67–70.

[38] Jia JD. Hepatitis B in China: from guideline to practice. Virol Sin 2008;23:283–292.

[39] Ma X, Zhang Q, He X, Sun W, Yue H, Chen S, Raymond HF, Li Y, Xu M, Du H, McFarland W. Trends in prevalence of HIV, syphilis, hepatitis C, hepatitis B, and sexual risk behavior among men who have sex with men. Results of 3 consecutive respondent-driven sampling surveys in Beijing, 2004 through 2006. J Acquir Immune Defic Syndr 2007;45:581–587.

[40] Hu Z, Liu Y, Zhai X, Dai J, Jin G, Wang L, Zhu L, Yang Y, Liu J, Chu M. New loci associated with chronic hepatitis B virus infection in Han Chinese. Nat Genet 2013;45:1499–501.

[41] Chen XL, Sun DX, Zhang XL. Hepatitis B virus genotypes. World J Gastroenterol 2011;04:389–393.

[42] Sun KK, Li J, Yan L, Sun MS, Ma JP, Chen J, Nie JJ, Zhuang H. Distribution of hepatitis B virus genotypes and subgenotypes in Chinese patients with chronic hepatitis B virus infection. Chinese Journal of Viral Diseases 2011;03:177–182.

[43] Gao JW, Li YJ, Zhuang H, Li J, Wang J, Dong QM, Chen YJ, Niu JQ, Ma WM, Deng Z, Shao Z. A novel B/C intergenotype recombinant of hepatitis B virus identified in north-west China. J Gen Virol 2014;95:153–155.

[44] Wang Z, Liu Z, Zeng G, Wen S, Qi Y, Ma S, Nauroum NV, Hou J. A new intertype recombinant of hepatitis B virus isolated from a patient with hepatitis B virus infection, identified in China. J Gen Virol 2005;86:985–990.

[45] Chen SJ, Zhao YY, Wang Z, Liu S, Jing L, Ji Z, Liu T, Liu CJ, Du Z. Detection of HBV relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994;198:489–503.

[46] Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infection in China over a 20-year period. Int J Infect Dis 2012;16:828–88.

[47] Liang XF, Bi SL, Wang WD, Cui G, Cui FQ, Zhang Y, Liu JH, Gong XH, Chen YS, Wang FZ, Zhang H, Wang F, Guo J, Jia ZY, Ma JC, Wang HQ, Luo HM, Li J, Jin SG, Hadler SC, Wang Y. Reprint of: Epidemiological survey of occult hepatitis B virus infection. Vaccine 2013;31:121–128.

[48] Yao J, Ying Y. Investigation on Immunization Coverage Rate and Immune Effect of Hepatitis B Vaccine among Newborns in Zhejiang Province. Chinese Journal of Vaccines and Immunizations 2000:6:132–134.

[49] Liu PB. Certain question discussion of hepatitis B vaccine inoculation. Chinese Journal of Public Health 2000;16:73–74.

[50] Nelson JC, Bittner RC, Bounds L, Zhao S, Bags J, Donaheu JG, Hammond SJ, Jacobsen SJ, Klein NP, Naylor AL, Zangwill KM, Jackson LA. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety data link study. Am J Public Health 2009;99 (Suppl 2):S389–397.

[51] Li XM, Shi MF, Yang YB, Shi ZJ, Hou HY, Shen HM, Teng BQ. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol 2007;13:3506–3509.

[52] Zou H, Chen Y, Duan Z, Zhang H. Protective effect of hepatitis B vaccine combined with two-dose hepatitis B immunoglobulin on infants born to HBsAg-positive mothers. PLoS one 2011;6:e26748.

[53] Yuan J, Lin J, Xu A, Li H, Hu B, Chen J, Yao J, Dong H, Jiang M, Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-centre randomized study. J Viral Hepat 2006;13:597–604.

[54] Xie SS, Li WL. HBV serum markers pattern in SHBAs2 workers. Chinese Journal of vocational medicine research 2005;145:1564–15654.

[55] Zhu QX, Zhang YT, Gu WP, Wang Q. A survey of hepatitis B virus infection in migrant workers in Xianju county from 2005 to 2007. Zhejiang Journal of Preventive Medicine 2009;21:25–25.

[56] Gong T, Gong Y, Deng D, Ye ML. A cross-sectional study on hepatitis B in migrant workers of Chongqing. Modern Preventive Medicine 2007;34:3842–3844.

[57] Zhang YB, Chen QJ, Hao YT, Chen WH, Ma ZC, Liao YX, Zhang R, Zhu QL. Comparisons and analysis of the hepatitis B infection status of transient population and registered residents in Shenzhen City. Chinese Journal of Disease Control and Prevention 2012;16:424–427.

[58] Xu DZ, Yan YP, Zou S, Choi BC, Wang S, Liu P, Bai G, Wang X, Shi M, Wang X. Role of placental tissues in the intraternal transmission of hepatitis B virus. Am J Obstet Gynecol 2001;185:981–987.

[59] Bai GQ, Li SH, Yue YF, Shi L. The study on role of peripheral blood mononuclear cell in HBV intrauterine infection. Arch Gynecol Obstet 2011;283:317–321.
Xu DZ, Yan YP, Choi BC, Xu JQ, Men K, Zhang JX, Liu ZH, Wang FS. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002;67:20–26.

van Nunen AB, de Man RA, Heijtink RA, Nieters HG, Schalm SW. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol 2000;32:1040–1041.

van Zonneveld M, van Nunen AB, Nieters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10:294–297.

Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol 2010;116:147–159.

MA QS, Zhou YH, Zhang SX, Liang S, Xiao HW, Xie X, Mei SJ, Jia WD, Zhang YF, Cui FQ, Wang FZ, Liang XF. Analysis on the direct economic burden and influence factors of HBV-related diseases in Guangzhou. China Preventive Medicine 2011;12:383–386.

Li XQ, Xu HX, Fan XM, Wu Z, Li YF, Zhang SX, Zhuang GH, Zhang LH. Analysis on economic burden and influencing factors of hepatitis B-related diseases patients. Modern Preventive Medicine 2012;39:1871–1874.

Lu JJ, Li RP, Xu AQ, Zhang L, Song LZ, Yan BY, Ji F, Liu JY, Fang XQ, Wang Z, Zhu DW, Zhang GJ, Feng Y, Xiao ZK, Wang J. Economic burden and related factors on inpatients with HBV-related diseases in Shandong province. Zhonghua Liu Xing Bing Xue Za Zhi 2013;34:267–272.